Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 67 of 114

  1. NKTR-214

    Nektar Therapeutics UK Limited

    Melanoma

    phase 3 mab completed

    1 trial

  2. NKTR-214

    Bristol-Myers Squibb

    Melanoma

    phase 3 mab completed

    1 trial

  3. NKTR-255 at 1.5 µg/kg

    Nektar Therapeutics UK Limited

    Non-Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  4. NL79088.041.21

    Disc Medicine

    Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise)

    phase 3 small molecule active

    1 trial

  5. NL79665.058.22

    Disc Medicine

    Cluster headache

    phase 3 small molecule active

    1 trial

  6. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    5 trials

  7. NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  8. NMRA-335140-303

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  9. NN1436-7724

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  10. NN1436-8182

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  11. NN1535-8377

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  12. NN6019-4958

    NovoThirteen

    Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy

    phase 3 small molecule active

    1 trial

  13. NN6535-4725

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  14. NN6535-4730

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  15. NN6535-7519

    NovoThirteen

    Mild cognitive impairment (MCI) or mild dementia, both of the Alzheimer’s type

    phase 3 small molecule active

    1 trial

  16. NN7415-4307

    NovoThirteen

    haemophilia A (HA) without inhibitors and haemophilia B (HB) without inhibitors

    phase 3 small molecule active

    1 trial

  17. NN7415-4311

    NovoThirteen

    haemophilia A (HA) with inhibitors and haemophilia B (HB) with inhibitors

    phase 3 small molecule active

    1 trial

  18. NN7415-4616

    NovoThirteen

    Haemophilia A or B with or without inhibitors

    phase 3 small molecule active

    1 trial

  19. NN8022-4392

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  20. NN8640-4263

    NovoThirteen

    Growth Hormone Deficiency in children

    phase 3 small molecule active

    1 trial

  21. NN8640-4467

    NovoThirteen

    Children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature

    phase 3 small molecule active

    1 trial

  22. NN9388-4895

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  23. NN9388-7637

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  24. NN9388-7741

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  25. NN9490-8021

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  26. NN9490-8024

    NovoThirteen

    Overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  27. NN9490-8025

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure

    phase 3 small molecule active

    1 trial

  28. NN9490-8026

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  29. NN9490-8028

    NovoThirteen

    Participants with overweight or obesity, and type 2 diabetes

    phase 3 small molecule active

    1 trial

  30. NN9490-8266

    NovoThirteen

    HFpEF or HFmrEF and obesity

    phase 3 small molecule active

    1 trial

  31. NN9490-8293

    NovoThirteen

    Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)

    phase 3 small molecule active

    1 trial

  32. NN9490-8294

    NovoThirteen

    Overweight or obesity, and knee osteoarthritis

    phase 3 small molecule active

    1 trial

  33. NN9490-8559

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  34. NN9535-4352

    NovoThirteen

    While it is well-established that long-term good glycaemic control will reduce the risk of diabetic retinopathy development and progression, intensification of glycaemic control has also been associated with an initial worsening of diabetic retinopathy. This phenomenon is known as “early worsening”. The rationale of this trial is to establish the long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (T2D) using validated and standardised ophthalmic assessments. This trial is a post-authorisation safety study (PASS) conducted as a commitment to the European Medicines Agency

    phase 3 small molecule active

    1 trial

  35. NN9535-4801

    NovoThirteen

    Participants with T2D and overweight

    phase 3 small molecule active

    1 trial

  36. NN9833-8242

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  37. NN9833-8243

    NovoThirteen

    Overweight and obesity

    phase 3 small molecule active

    1 trial

  38. NN9838-4608

    NovoThirteen

    Overweight and obesity

    phase 3 other active

    1 trial

  39. NN9838-4609

    NovoThirteen

    Overweight and obesity and type 2 diabetes

    phase 3 small molecule active

    1 trial

  40. NN9838-4942

    NovoThirteen

    Cardiovascular disease

    phase 3 small molecule active

    1 trial

  41. NN9838-7749

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  42. NN9838-7859

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  43. NN9924-4437

    NovoThirteen

    Type 2 diabetes

    phase 3 small molecule active

    1 trial

  44. NN9931-4553

    NovoThirteen

    Non-alcoholic steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  45. NNC0487-0111

    Novo Nordisk A/S

    Obesity

    phase 3 small molecule active

    1 trial

  46. NOE-TGN-201

    Lacuna Pharma Pty Ltd

    Trigeminal neuralgia, Trigeminal neuralgia

    phase 3 small molecule active

    1 trial

  47. NOPRODPAPUH3001

    Lacuna Pharma Pty Ltd

    pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  48. NORADRENALINA TARTRATO MONICO 2 mg/ml Concentrato per soluzione per infusione

    Lacuna Pharma Pty Ltd

    criticall illness

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.